COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022

Jonas Björk1,2, Carl Bonander3, Mahnaz Moghaddassi4, Magnus Rasmussen5, Ulf Malmqvist2, Malin Inghammar5, Fredrik Kahn5
1. Clinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden
2. Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden
3. School of Public Health and Community Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
4. Social Medicine and Global Health, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden
5. Department of Clinical Sciences Lund, Section for Infection Medicine, Skåne University Hospital, Lund University, Lund, Sweden

Correspondence: Jonas Björk (jonas.bjork@med.lu.se)

Citation style for this article:
Björk Jonas, Bonander Carl, Moghaddassi Mahnaz, Rasmussen Magnus, Malmqvist Ulf, Inghammar Malin, Kahn Fredrik. COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022. Euro Surveill. 2022;27(18):pii=2200322. https://doi.org/10.2807/1560-7917.ES.2022.27.18.2200322

We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron (Phylogenetic Assignment of Named Global Outbreak (Pango) lineage designation B.1.1.529) has two genetically divergent subvariants, BA.1 and BA.2 that emerged in late 2021 and early 2022, respectively. A comparison of secondary attack rates from Denmark suggests that the BA.2 subvariant carries a transmission advantage compared with BA.1 [1], which may explain why BA.2 has rapidly replaced BA.1 as the dominant subvariant in several countries. A study from the United Kingdom suggests comparable vaccine protection against symptomatic disease from BA.2 as for BA.1 [2]. However, few studies have compared the protection against severe disease from these two Omicron subvariants. Recent findings from Qatar suggested lower vaccine protection against hospitalisations and deaths from BA.2 but with a very wide confidence interval [3].

We aimed to compare COVID-19 vaccine effectiveness (VE) against severe disease from the Omicron BA.1 and BA.2 subvariants, in Scania county, southern Sweden, a region with routine sequencing of samples of infected cases.

Studied population and period
The study cohort included all individuals residing in Scania county (Skåne), southern Sweden, on 27 December 2020 (baseline) when COVID-19 vaccinations began (n=1,384,531) [4,5]; this cohort was followed longitudinally for positive SARS-CoV-2 tests, hospitalisations and assessment of disease severity. Individuals who died or moved away from the region were censored on the date of death or relocation.

We used available data from routine sequencing of samples of infected cases in Scania county (Supplementary Table S1) to define three specific follow-up periods for the evaluation of VE in the present study, during which the proportion of BA.2 surpassed BA.1 and the Omicron the Delta (Pango lineage designation B.1.617.2) VOC. These calendar periods were: (i) Omicron BA.1 as the dominating VOC, week 52 2021 – week 1 2022 (respective proportions of SARS VOCs – BA.1: 60%, Delta: 25%, BA.2: 15%), (ii) transition period, week 2–3 2022 (BA.1: 47%, Delta: 4.5%, BA.2: 49%), and (iii) Omicron BA.2 as the dominating VOC, week 4–11 2022 (until date of data extraction on 15 March – BA.1: 17%, Delta: 0.5%, BA.2: 82%).

Data extraction and case definition
Demographic and clinical data collected from national and regional register holders were linked using the personal identification number assigned to all Swedish residents. Weekly updates on vaccination date, type of vaccine and dose were obtained from the National
Table 1

Characteristics of severe COVID-19 cases (n = 593) and controls (n = 5,930), stratified by follow-up period for monitoring of vaccine effectiveness during SARS-CoV-2 Omicron variant dominance, Scania, Sweden, 2021 week 52–2022 week 11

| Characteristics | Follow-up period | Omicron BA.1 (2021 w52–2022 w1) | Transition (2022 w2–3) | Omicron BA.2 (2022 w4–11) |
|-----------------|------------------|----------------------------------|-------------------------|--------------------------|
|                 | Cases (n = 129)  | Controls (n = 1,290)             | Cases (n = 156)         | Controls (n = 1,560)     |
|                 | Controls (n = 78) | NA                               | Controls (n = 56)       | NA                       |
| Weekly case rate, mean (n) | 65 | NA | 78 | 56 |
| Age group (years) % n | % | % | % | % |
| 0–17            | 3.1 4 47 3.6 | 4.3 67 5.2 16 5.1 | 16 5.1 156 |
| 18–39           | 16 21 198 9.0 | 14 157 12 37 12 | 364 |
| 40–64           | 30 39 392 23 | 36 37 15 47 17 | 523 |
| ≥65             | 50 65 653 63 | 96 68 62 69 66 | 208 66 2,037 |
| Sex Female % n | % | % | % | % |
| Male            | 37 48 480 38 | 60 600 50 153 50 | 1,530 |
| Born abroad % n | % | % | % | % |
| Married % n     | 45 58 611 36 | 56 746 37 113 47 | 1,460 |
| Widow/widower   | 8.5 11 114 15 | 24 176 16 48 15 | 462 |
| Divorced % n    | 21 27 197 21 | 33 259 23 70 14 | 443 |
| Single % n      | 26 33 277 32 | 50 309 23 70 18 | 561 |
| Comorbidities % n | % | % | % | % |
| 0               | 36 46 816 38 | 59 905 33 103 56 | 1,736 |
| 1               | 26 33 273 26 | 40 362 25 78 25 | 758 |
| ≥2              | 39 50 201 36 | 19 293 41 127 19 | 586 |
| Vaccine doses % n | % | % | % | % |
| 0               | 54 70 14 185 | 65 201 27 82 13 | 394 |
| 1               | 3.1 4 23 4.5 | 7 28 4.5 14 1.6 | 50 |
| 2               | 18 23 481 28 | 44 459 20 62 17 | 519 |
| 3               | 25 32 601 26 | 40 872 49 150 68 | 2,108 |
| 4               | 0.0 0 0 0.0 | 0.0 0.0 0.0 0.0 | 0.0 |
| Vaccine type % n | % | % | % | % |
| Comirnaty       | 74 41 775 71 | 60 934 73 155 69 | 1,825 |
| Spikevax        | 3.6 2 73 13 | 11 4.9 65 4.7 10 4.3 | 114 |
| Vaxzevria       | 3.6 2 25 4.8 | 2 27 2.4 5 1.0 | 26 |
| Mixed           | 18 10 209 11 | 9 305 20 42 26 | 671 |
| Time since last vaccine dose % n | % | % | % | % |
| 0–3             | 54 30 650 43 | 36 884 38 80 56 | 1,470 |
| 3–6 months      | 20 11 288 27 | 23 256 43 92 35 | 933 |
| ≥6 months       | 26 14 144 30 | 25 191 19 40 8.8 | 233 |
| Prior SARS-CoV-2 infection % n | % | % | % | % |
| 2.3             | 3 8.8 114 3.8 | 8.2 128 5.8 18 8.1 | 250 |
| At least two doses or prior SARS-CoV-2 infection % n | % | % | % | % |
| 43 56 85 1,101 54 87 1,353 70 216 87 | 2,675 |

COVID-19: coronavirus disease; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

---

### Notes

- Last two weeks of the Omicron BA.2 was not included in the calculation of weekly case rate in order to limit the impact of delay in manifestation of severe cases.
- Only persons with at least two doses.

A severe COVID-19 case was defined as a case who was hospitalised for at least 24 h from 5 days before until 14 days after a positive SARS-CoV-2 test and required oxygen supply (≥ 5 L/min) or admittance to an intensive care unit (ICU). For each severe case, 10 controls without a positive test the same week as the case or 90 days prior were randomly selected from the underlying study cohort, matched with respect to sex and age (5-year groups).
The following vaccines were used during the study period: Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer), Spikevax (mRNA-1273, Moderna), Vaxzevria (ChAdOx1-S, AstraZeneca). Estimated vaccine effectiveness obtained from conditional logistic regression for age and sex matched case and controls (1:10). Solid black curves indicate vaccine effectiveness. Grey dotted lines represent 95% confidence intervals.

Vaccine effectiveness

Comorbidities were defined from diagnoses in inpatient or specialised care at any time point during the 5 years before baseline in the following disease groups: cardiovascular diseases, diabetes or obesity, kidney or liver diseases, respiratory diseases, neurological diseases, cancer or immunosuppressed states, and other conditions and diseases (Down syndrome, HIV, sickle cell anaemia, drug addiction, thalassaemia or mental health disorder) (for a detailed list see Supplementary Table S2: Classification of comorbidities). The number of comorbidities in these groupings was counted and used in the analyses.

A severe COVID-19 case was defined as a case who was hospitalised for at least 24 h from 5 days before until 14 days after a positive SARS-CoV-2 test and required oxygen supply (≥ 5 L/min) or admittance to an intensive care unit (ICU).

Vaccine effectiveness

We used continuous density case–control sampling [6] nested within the study cohort together with conditional logistic regression to estimate VE against severe COVID-19. For each severe case, 10 controls without a positive SARS-CoV-2 test the same week as the case or 90 days prior were randomly selected from the underlying study cohort, matched with respect to sex and age (5-year groups). Only vaccine doses obtained more than 7 days before the positive test of the case were counted in the analyses. Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) was most frequently used vaccine type, representing 77% of all administrated doses in the study cohort; Spikevax (mRNA-1273, Moderna) and Vaxzevria (ChAdOx1 nCoV-19, Oxford-AstraZeneca) were also used in the vaccination program.

A total of 593 severe COVID-cases occurred during the study period, corresponding to 65, 78 and 56 cases weekly during the Omicron BA.1, the transition and Omicron BA.2 periods, respectively (Table 1). Severe cases during the BA.2 period were older and had a more even sex distribution versus the BA.1 period. The overrepresentation of individuals born abroad among severe cases observed during BA.1 was less marked during BA.2, but the presence of comorbidities was similar. The monthly surveillance shows that population protection against severe COVID-19 after at least two doses was high before the follow-up periods of the present study started (median VE: 89% during March–November 2021) (Figure 1). Population protection remained stable also during the Delta and Omicron BA.1 dominance in December 2021, whereas the transition from Omicron BA.1 to BA.2 in January–February 2022 was associated with a decline in protection.

In more detailed analyses of the change in VE, numbers of vaccine doses were grouped as 0–1, 2 or at least 3 and we adjusted for the number of comorbidities and infection at least 90 days before the case date. Whereas the VE after at least three doses remained above 80% throughout the study period, VE after two doses declined substantially from 90% (95% confidence interval (CI)): 78–95) during Omicron BA.1 dominance to 54% (95% CI: 13–75) during BA.2 dominance (Figure 2 and Supplementary Table S3: Vaccine effectiveness after at least three or two doses against severe COVID-19). This decline was consistently noted across subgroups of age, sex and comorbidities.

We also compared the protection from vaccination and infection history (Table 2). Surviving a prior SARS-CoV-2 infection offered similar protection against new onset of severe COVID-19 as two or three vaccine doses both during Omicron BA.1 dominance and the transition period. However, the protection associated with prior infection and at most two doses decreased markedly during Omicron BA.2 dominance, whereas the protection against severe COVID-19 associated with at least three doses remained at high levels.

Discussion

The main finding of the present study was the marked decline in protection against severe COVID-19 during...
Omicron BA.2 dominance among persons with two vaccine doses only. The decline occurred quite rapidly over two months and thus cannot be explained by waning VE alone. A more likely explanation is increased immune evasiveness properties of BA.2, which gives this genetically distinct subvariant a competitive advantage in highly vaccinated populations [1].

The relatively stable protection among individuals with at least three doses during follow-up in our study suggests that a very robust immune response is necessary to confer protection also against BA.2.

Although the overall vaccination uptake of two doses among adults is high (83%) in the study cohort; only 57% had accepted the booster dose that was generally offered to everyone in Scania by the end of the study period. The Scania region is ethnically and socio-economically diverse and we have previously reported substantially lower vaccination uptake among population groups born outside Sweden [7]. In the current study, the overrepresentation of foreign-born individuals among cases with severe disease decreased during the transition from BA.1 to BA.2, which suggests more widespread dropouts from the vaccination programme after two doses also among people born in Sweden. This means that the overall population protection against severe COVID-19 can be insufficient in case of new intermittent SARS-CoV-2 epidemics that may become the 'new normal' [8].

Another notable finding was that the protection associated with a prior SARS-CoV-2 infection also declined after the transition from Omicron BA.1 to BA.2. A recent total population study from Sweden reported long-lasting protection among unvaccinated persons who have survived and recovered from a previous SARS-CoV-2 infection [9]. However, the follow-up of that study ended before Omicron became dominant. Our study, with a more recent follow-up, suggests that the natural protection from previous VOCs against severe disease is markedly lower when Omicron BA.2 is dominant.

The key strengths of our study were the detailed individual-level data on vaccinations, infections and hospitalisations and the possibility to stratify hospitalised people further by disease severity, thereby limiting the misclassification of cases hospitalised with – rather than because of – COVID-19. A major limitation was that we lacked data on the virus variant for the individual cases in each time period. Our study may therefore underestimate the true change in VE associated with the transition from BA.1 to BA.2. Another limitation was that we could not evaluate protection from prior Omicron infection, as the follow-up period with

**Figure 2**

Vaccine effectiveness against severe COVID-19 in each follow-up period during SARS-CoV-2 Omicron variant dominance, Scania, Sweden, 2021 week 52 – 2022 week 11 (n = 593 cases; n = 5,930 controls)

**Table 1**

| Vaccine effectiveness (%) | Vaccine effectiveness (%) |
|---------------------------|---------------------------|
| COVID-19: coronavirus disease; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2. | Omicron BA.1 period 2021 w52–2022 w1 (blue boxes; n=129 cases; n=1,290 controls), transition period 2022 w2–3 (gray circles; n = 156 cases; n = 1,560 controls), Omicron BA.2 period 2022 w4–11 (pink triangles; n = 308 cases; n = 3,080 controls) after at least three (A) or two doses (B) of COVID-19 vaccine. Shapes represent point estimates and lines 95% confidence intervals. |
| The following vaccines were used during the study period: Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer), Spikevax (mRNA-1273, Moderna), Vaxzevria (ChAdOx1-S, AstraZeneca). | Estimates were obtained from conditional logistic regression for age and sex matched case and controls (1:10), and with adjustment for comorbidities (0, 1, ≥ 2) and infection at least 90 days prior the case date. Results are presented overall and stratified by age, sex and comorbidities. |

| Vaccine effectiveness (%) | Vaccine effectiveness (%) |
|---------------------------|---------------------------|
| A. At least three doses | B. Two doses |
| All | All |
| Age < 65 y | Age < 65 y |
| Age ≥ 65 y | Age ≥ 65 y |
| Females | Females |
| Males | Males |
| No comorbidities | No comorbidities |
| Comorbidities (≥ 1) | Comorbidities (≥ 1) |
| 0 | 10 |
| 20 | 30 |
| 40 | 50 |
| 60 | 70 |
| 80 | 90 |
| 100 | 100 |

| Vaccine effectiveness (%) | Vaccine effectiveness (%) |
|---------------------------|---------------------------|
| | | |
Omicron dominates is still short. Evidence from Qatar suggests that infection from BA.1 protects against reinfection with BA.2 but this was observed during a very short follow-up period [10]. A further limitation of our study was that general testing was no longer generally recommended in Sweden, which means that VE against infection could not be evaluated. It should also be noted that the statistical uncertainty in some of our subgroups was substantial, as reflected by the wide and overlapping CIs across the follow-up periods. Continued monitoring of VE associated with Omicron BA.2 is therefore warranted.

**Conclusion**

VE remained relatively stable after the transition from the Omicron BA.1 to BA.2 subvariant among people with at least three doses but point estimates decreased markedly among those with only two doses. Protection from prior infection was also lower when BA.2 was dominant. These findings from our population-based study suggest that booster vaccination is needed to maintain sufficient protection against severe COVID-19.

### Table 2

| Vaccination and infection history | Omicron BA.1 | Omicron BA.2 |
|----------------------------------|--------------|--------------|
|                                  | 2021 W52–2022 W1 | 2022 W4–11 |
| Protection | 95% CI | Protection | 95% CI |
| 0 – 1 dose | Reference | Reference |
| 0 – 1 dose + prior infection | 81 | 0–98 | 85 | 0–98 |
| 2 doses | 91 | 79–96 | 70 | 41–85 |
| 2 doses + prior infection | 91 | 57–98 | 92 | 59–98 |
| ≥ 3 doses | 94 | 83–98 | 92 | 83–96 |
| ≥ 3 doses + prior infection | 100 | NA | 85 | 47–96 |

CI: confidence interval; COVID-19: coronavirus disease; OR: odds ratio; SARS: severe acute respiratory syndrome coronavirus 2.

| Follow-up period | Transition |
|------------------|------------|
| Protection | 95% CI |
| 0 – 1 dose | Reference |
| 0 – 1 dose + prior infection | 81 | 0–98 |
| 2 doses | 91 | 79–96 |
| 2 doses + prior infection | 91 | 57–98 |
| ≥ 3 doses | 94 | 83–98 |
| ≥ 3 doses + prior infection | 100 | NA |

CI: confidence interval; COVID-19: coronavirus disease; OR: odds ratio; SARS: severe acute respiratory syndrome coronavirus 2.

| Follow-up period | Omicron BA.2 |
|------------------|--------------|
| Protection | 95% CI |
| 0 – 1 dose | Reference |
| 0 – 1 dose + prior infection | 81 | 0–98 |
| 2 doses | 91 | 79–96 |
| 2 doses + prior infection | 91 | 57–98 |
| ≥ 3 doses | 94 | 83–98 |
| ≥ 3 doses + prior infection | 100 | NA |

The funders played no role in the design of the study, data collection or analysis, decision to publish, or preparation of the manuscript.

**Acknowledgements**

Cecilia Åkesson-Kotsaris, Paul Söderholm and Helena Hallefjord, Clinical Studies Sweden, for excellence in bringing the surveillance infrastructure in place. Claus Bohn Christiansen, Scania Region, Clinical microbiology, for providing data from routine sequencing of infected cases.

**Conflict of interest**

None declared.

**Authors’ contributions**

JB and FK conceived the study, with important contributions from CB, MM, MR, UM and MI. UM, JB and MM acquired data, CB, JB and MM conducted the statistical analyses. JB drafted the manuscript with assistance from FK and MI. All authors contributed with interpretation of results, critically revised the manuscript and approved the final version for submission.

**References**

1. Lyngse FP, Kirkeby CT, Denwood M, Christiansen LE, Mølbak K, Mellor CH, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish households. medRxiv. 2022.01.28.22270044. Preprint. https://doi.org/10.1101/2022.01.28.22270044
2. Kirsebom FCM, Andrews N, Stowe J, Toffa S, Sachdeva R, Gallagher E, et al. COVID-19 Vaccine Effectiveness against the Omicron BA.2 variant in England. medRxiv. 2022.03.22.22272691. Preprint. https://doi.org/10.1101/2022.03.22.22272691
3. Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar. medRxiv.
4. Björk J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F. High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population - first results from a cohort study in Southern Sweden. Infect Dis (Lond). 2022;54(2):128-33. https://doi.org/10.1080/23744235.2021.1982144 PMID: 34586934

5. Kahn F, Bonander C, Moghaddassi M, Rasmussen M, Malmqvist U, Inghammar M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveill. 2022;27(9):2200121. https://doi.org/10.2807/1560-7917.ES.2022.27.9.2200121 PMID: 35241215

6. Dean NE. Re: “Measurement of vaccine direct effects under the test-negative design”. Am J Epidemiol. 2019;188(4):806-10. https://doi.org/10.1093/aje/kwz019 PMID: 30689690

7. Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F, Björk J. COVID-19 vaccine uptake among older people in relation to sociodemographic factors - cohort results from southern Sweden. medRxiv. 2021.08.12.21261981. Preprint. https://doi.org/10.1101/2021.08.12.21261981

8. Eales O, de Oliveira Martins L, Page AJ, Wang H, Bodinier B, Tang D, et al. The new normal? Dynamics and scale of the SARS-CoV-2 variant Omicron epidemic in England. medRxiv. 2022.03.29.22273042. Preprint. https://doi.org/10.1101/2022.03.29.22273042

9. Nordström P, Ballin M, Nordström Å. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis. 2022;S1473-3099(22)00143-8. PMID: 35366962

10. Chemaitelly H, Ayoub HH, Coyle P, Tang P, Yassine HM, Al-Khatib HA, et al. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. medRxiv. 2022.02.24.22271440. Preprint. https://doi.org/10.1101/2022.02.24.22271440

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2022.